Drugs / ENC-201-CED hPI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06408311 | May 2024 → Jul 2026 overdue | type 1 diabetes mellitus | Encellin | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENC-201-CED hPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06408311 ↗ |
| Modality | Cell therapy | “macro-encapsulated human primary islets” NCT06408311 ↗ |
| Route | Subcutaneous | “in a subcutaneous space” NCT06408311 ↗ |